STOCK TITAN
  1. Home
  2. News
  3. ABT

Abbott Laboratories - ABT STOCK NEWS

Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.

Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.

Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.

Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.

Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.

Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.

News

FDA Advisory Committee Votes in Favor of Abbott's First-of-Its-Kind TriClip™ System to Treat People With a Leaky Tricuspid Heart Valve

Rhea-AI Summary
Abbott's TriClip system for tricuspid regurgitation receives positive review from FDA advisory committee, showing safety, effectiveness, and quality-of-life benefits. The device has been approved in over 50 countries and has treated over 10,000 patients worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
none
-
News

New Study Shows Mixed Reality Technology for Blood Donation From Abbott and Blood Centers of America Helps Ease Stress, Encourages People To Donate Again

Rhea-AI Summary
Abbott (NYSE:ABT) and Blood Centers of America (BCA) have partnered to launch a mixed reality experience for blood donors, designed to ease feelings of anxiety and increase donor retention. Results from the pilot study show that 68.4% of donors who reported pre-donation anxiety felt less anxious using mixed reality, and 89.2% of donors said they were likely to donate blood again. The technology aims to attract new donors and motivate a younger generation to give blood, addressing the global challenge of sustaining a reliable blood supply.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
-
News

Decade of Impact: Transforming Care in Tanzania

Rhea-AI Summary
Abbott's emergency medicine pioneers have provided care for over 1.2 million people, including a pregnant woman in Tanzania who needed advanced health care during heavy rains. This demonstrates the company's commitment to global healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
none
News

Abbott Launches New PROTALITY(TM) Brand To Support Adults on Their Weight Loss Journey

Rhea-AI Summary
Abbott (NYSE:ABT) has announced the launch of its new PROTALITY™ brand, offering a high-protein nutrition shake to support weight loss while preserving muscle mass and good nutrition. The shake contains 30 grams of high-quality protein, 8 essential B vitamins, 4 grams of comfort fiber, 1 gram of sugar, 150 calories, and 25 vitamins and minerals. The product is now available online and at various retailers, catering to adults interested in pursuing weight loss while maintaining muscle health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
-
News

Can a 'Food as Medicine' Approach Help Manage Diabetes?

Rhea-AI Summary
Abbott's partnership with the Emergency Food Bank of Stockton, Calif. has led to encouraging results in delivering healthy meal boxes to people with diabetes. Nutrition educator Alex Marapao emphasizes the use of olive oil in cooking demonstrations, promoting healthy habits to combat diabetes. The mission is to share nutrition education that takes root in the community and grows healthy habits for generations to come.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
none
-
News

New Study Shows Mixed Reality Technology for Blood Donation from Abbott and Blood Centers of America Helps Ease Stress, Encourages People to Donate Again

Rhea-AI Summary
A new study published in the journal Transfusion reveals that Abbott and Blood Centers of America's mixed reality technology for use during blood donation helps ease donors' feelings of anxiety and boosts the likelihood they will return to give blood again. The pilot study examined the experiences of 282 blood donors who tried mixed reality at 54 collection sites in Houston and the Quad Cities area in Iowa and Illinois. 68.4% of donors who reported pre-donation anxiety said the mixed reality experience helped ease their anxiety, and 89.2% of donors who tried mixed reality said they were likely to donate blood again. The mixed reality experience is an immersive digital experience designed to improve the blood donation process, attract new donors, and motivate a younger generation to give blood. It is now available at several donation sites across the country, including in New York, Houston, and the Chicago area.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
News

Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey

Rhea-AI Summary
Abbott (NYSE: ABT) has launched its new PROTALITY™ brand, offering a high-protein nutrition shake to support weight loss while preserving muscle mass. The brand is aimed at adults pursuing weight loss, with the first product featuring 30 grams of protein, essential B vitamins, comfort fiber, and 150 calories. The shake is now available online and at various retailers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
News

Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+

Rhea-AI Summary
Abbott (NYSE: ABT) has received FDA approval for the Liberta RC™ deep brain stimulation (DBS) system, the world's smallest rechargeable DBS device with remote programming. It offers the longest time between charges of any DBS technology on the market, requiring only 10 recharge sessions a year for most people. The system features NeuroSphere™ Virtual Clinic, allowing remote communication with doctors, ensuring proper settings and functionality, and receiving new treatment settings without visiting a doctor's office.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
News

Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook

Rhea-AI Summary
Abbott announced fourth-quarter sales increase of 1.5 percent, full-year 2023 reported sales decreased by 8.1 percent due to COVID-19 testing-related sales; organic sales growth increased by 11.6 percent. The company projects full-year 2024 organic sales growth to be in the range of 8.0% to 10.0%. The R&D pipeline continues to deliver new products, and the company has regained its market-leading position in the U.S. infant formula market. Abbott's new laboratory automation system, GLP systems Track™, received FDA approval, and the company's Volt™ Pulsed Field Ablation System was used for the first time in humans. Abbott's Tandem Diabetes Care's t:slim X2™ insulin pump is now the first automated insulin delivery system in the U.S. to integrate with Abbott's new FreeStyle Libre® 2 Plus sensor. The company's EPS was $3.26 for full-year 2023 and projects a diluted EPS on a GAAP basis of $3.20 to $3.40 for full-year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
earnings
News

Continuing to Lead the Way in Sustainability

Rhea-AI Summary
Abbott has earned the top overall industry score for 11 years and leads in health access on the global sustainability benchmark DJSI. The company's 2030 Sustainability Plan aims to improve the health of 3 billion people annually by 2030, with a focus on connecting care and technology to put people in control. Abbott also achieved top scores in key social, environmental, and governance categories on the S&P Global Corporate Sustainability Assessment, confirming its position as a leader in sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none

FAQ

What is the current stock price of Abbott Laboratories (ABT)?

The current stock price of Abbott Laboratories (ABT) is $115.9 as of November 15, 2024.

What is the market cap of Abbott Laboratories (ABT)?

The market cap of Abbott Laboratories (ABT) is approximately 200.2B.

What does Abbott Laboratories specialize in?

Abbott Laboratories specializes in cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

What are some of Abbott’s recent product launches?

Recent product launches include the PROTALITY™ high-protein nutrition shake and the TriClip™ system for tricuspid valve repair.

How much of Abbott’s sales are generated outside the United States?

Approximately 60% of Abbott’s sales are generated outside the United States.

What is Abbott’s PROTALITY™ brand?

The PROTALITY™ brand is a high-protein nutrition shake designed to support weight loss while preserving muscle mass, addressing global health challenges like obesity.

How does Abbott support global health initiatives?

Abbott supports global health initiatives through strategic partnerships like their collaboration with the Real Madrid Foundation to reduce childhood malnutrition and promote healthy habits.

What is Abbott’s financial performance like?

Abbott has demonstrated robust financial performance, with strong Q1 2024 results and a consistent track record of dividend payouts, evidenced by its inclusion in the S&P 500 Dividend Aristocrats Index.

How many employees does Abbott have?

Abbott employs over 114,000 people worldwide.

Which continuous glucose monitoring system is Abbott known for?

Abbott is known for its FreeStyle Libre continuous glucose monitoring systems, which are widely recognized for their innovation in diabetes management.

What is Abbott's mission?

Abbott's mission is to help people live more fully at all stages of life by developing life-changing technologies spanning diagnostics, medical devices, nutritionals, and branded generic medicines.

In how many countries does Abbott operate?

Abbott operates in more than 160 countries worldwide.

Stock ABT logo
Abbott Laboratories

NYSE:ABT

ABT Rankings

#51 Ranked by Market Cap
#1422 Ranked by Dividends

ABT Stock Data

200.24B
1.73B
0.53%
78.64%
0.81%
Medical Devices
Pharmaceutical Preparations
Link
United States of America
ABBOTT PARK